The role of abemaciclib in treatment of advanced breast cancer

Until recently, the mainstay of treatment in the majority of hormone receptor (HR)-positive, human epidermal growth factor 2 receptor (HER2)-negative advanced breast cancer (ABC) has consisted of single-agent endocrine therapy (ET). However, as understanding of endocrine resistance has grown, newer...

Descripción completa

Detalles Bibliográficos
Autores principales: McCartney, Amelia, Moretti, Erica, Sanna, Giuseppina, Pestrin, Marta, Risi, Emanuela, Malorni, Luca, Biganzoli, Laura, Di Leo, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985604/
https://www.ncbi.nlm.nih.gov/pubmed/29899762
http://dx.doi.org/10.1177/1758835918776925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985604/
https://www.ncbi.nlm.nih.gov/pubmed/29899762
http://dx.doi.org/10.1177/1758835918776925

Ejemplares similares